Genomic Profiles for Disease Risk

Personal genomics and individual identities: motivations and moral imperatives of early users

“…Aside from these individual cases our data does not substantiate bioethical and medical experts’ concern that consumers of DTC genome scans will seek medical interpretation of their results without additional knowledge of the implications of heritable risk factors (e.g., McGuire and Burke 2008, Offit 2008). This is not to suggest that these experts’ concerns may not be realized if genome scanning is more widely adopted outside of the circle of thoughtfully invested early users.…”

Interest in genetic susceptibility testing and disclosure of AD dementia risk in cognitively normal adults: a survey study

“…Commercially available direct-to-consumer genetic screening tests including APOE genotype have become more widely available, and the interest among the general population in genetic susceptibly testing increases [ 51 , 61 , 62 ]. With the current increase in interest in commercially available APOE-genetic screening tests [ 45 ], like 23andMe, and associated requests to explain genetic results [ 58 ], and growing demand of personalised dementia risk reduction [ 56 ], the need for accurate education about genetic risk and disclosure impact arises.…”

Disclosure ofAPOEGenotype for Risk of Alzheimer's Disease

“…These concerns are amplified by the recent emergence of companies offering direct-to-consumer genetic testing, with most of them evaluating single-nucleotide polymorphisms that indicate the APOE genotype,1-3 in the absence of guidelines for deciding which associations between genes and disease have sufficient clinical validity and usefulness to justify disclosure and with no gauge of the effect of such disclosure. Caution is thus warranted, and empirical data are valuable.…”